IDIS to Sponsor Inaugural Conference on Pre-Launch Access to Drugs
LONDON, Sept. 18 /PRNewswire/ -- IDIS, the world leader in the development and implementation of Named Patient Programs (NPPs), will sponsor the first-of-its-kind conference on pre-launch access to drugs in Baltimore, MD, on October 22-23. This conference will bring together industry experts to present and exchange information on programs that enable patients with unmet medical needs to get access to drugs in the pre-launch phase. Industry leaders will discuss the fundamentals of US-based expanded access programs (EAPs) and global named patient programs, the best strategies for development of such programs, the optimal timing for programs, and their overall management. Internet access to information about drugs in late-stage clinical trials or approvals in certain countries has created a more informed and empowered population of patients who are taking a more aggressive approach to their health. This has brought about an increased demand for access to pre-launch drugs amongst patients when all other therapeutic options have been exhausted. Fortunately, government sanctioned EAPs and NPPs are in place to help drug developers respond to such requests. This conference, produced by the Center for Business Intelligence (CBI), is geared towards pharmaceutical and biotechnology company decision makers from global brand groups, regulatory, medical affairs, supply/logistics and other functions involved in patient access programs. The conference will provide a forum by which these companies can learn how these programs benefit patients as well as the sponsoring company, as well as the best way to execute these programs to ensure they are conducted in a manner consistent with regulations that vary by country. It will also offer extensive opportunities for networking and discussion with senior policy and decision makers.
Registration is currently being accepted at: https://www.cbireg.com/webreg/RegGate.wbr?PC08093 . Additional information about the conference is available at: http://www.cbinet.com/show_conference.cfm?confCode=PC08093 . About IDIS Founded in 1987, IDIS is the global leader in the development, implementation, and management of strategic solutions that provide access to unlicensed medicines across global markets via Named Patient Programs. Pharmaceutical and biotechnology companies of all sizes partner with IDIS to provide patients with genuine, unmet medical need access to potentially life-saving medicines.
IDIS is headquartered near central London. Visit the IDIS website at http://www.idispharma.com . About CBI (www.cbinet.com) A subsidiary of Advanstar Communications, CBI Research, Inc. is dedicated to developing market-driven, unbiased conferences in pharmaceuticals\biotech, medical devices, risk and insurance and managed care markets. CBI Research, Inc. offers conferences and summits that serve senior executives and government officials by providing a unique platform for highly focused content and presentation.
For further information on IDIS contact: Lynn Blenkhorn Feinstein Kean Healthcare (508) 851-0930
More by this Source
Suzanne Gagnon, M.D. Joins Idis As Chief Medical Officer
Mar 12, 2013, 07:05 ET
Natalie Douglas, CEO of Idis, Joins Global Genes | RARE Project Board of Directors
Feb 12, 2013, 07:05 ET
Natalie Douglas, CEO von Idis, tritt Vorstand von Global Genes | RARE Project bei
Feb 12, 2013, 01:05 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.